Infants have increased susceptibility to respiratory viral infections, with RSV and RV being the leading pathogens as they cause acute bronchiolitis and are associated with development of recurrent wheezing and asthma.

Background The role of SARS‐CoV‐2 as the cause of chilblains in children remains a matter of debate but it is important to elucidate it for patient isolation and contact tracing. We sought to define the etiology, clinical presentation, time course, and outcomes of children presenting to the emergency department (ED) with cutaneous manifestations shortly after the first pandemic peak of COVID‐19 in Spain. Methods A prospective, observational study in children <15 years of age evaluated for skin lesions in the EDs of three pediatric hospitals. Children underwent a comprehensive work‐up including tests for SARS‐CoV‐2 antibodies and polymerase chain reaction (PCR), and serology and PCR tests for other viruses and bacteria. A 1 month follow‐up visit was conducted. Results From April 14 through May 8, 2020, we enrolled 62 children. Of those, 34 had acro‐ischemic skin lesions and 28 had a variety of skin rashes. Overall, 40% of children had mild systemic symptoms. Children with chilblains were older, had pain more frequently and a more prolonged duration of skin lesions, while those with non‐specific rashes had fever more frequently. Lesions were resolved in 75% of children at follow up. Five patients demonstrated SARS‐CoV‐2 antibodies, and none tested positive with PCR. Three additional patients tested positive with PCR for rhinovirus, Mycoplasma pneumoniae and Chlamydia pneumoniae. Conclusions The number of ED visits for chilblains, which are rare in pediatrics, was high soon after the first peak of COVID‐19 in Spain. The disease course was self‐limited, outcomes were favorable, and the possibility of viral transmission was negligible as all patients tested negative for SARS‐CoV‐2 by PCR.

No abstract

No abstract

No abstract

No abstract